ストックスクリーナーアプリを入手
2.2301
5.10%
-0.1199
プレマーケット:
2.38
0.1499
+6.72%
前日終値:
$2.35
開ける：
$2.29
24時間の取引高:
8,023
Relative Volume:
0.32
時価総額：
$15.60M
収益：
-
当期純損益:
$-33.65M
株価収益率:
-0.5011
EPS:
-4.45
ネットキャッシュフロー:
$-20.83M
1週間 パフォーマンス:
-3.04%
1か月 パフォーマンス:
-6.69%
6か月 パフォーマンス:
-26.25%
1年 パフォーマンス:
-69.24%
1日の値動き範囲:
$2.21
$2.29
1週間の範囲:
$2.21
$2.40
52週間の値動き範囲:
$2.06
$13.49
Minerva Neurosciences Inc Stock (NERV) Company Profile
名前
Minerva Neurosciences Inc
セクター
電話
617-600-7373
住所
1601 TRAPELO ROAD, WALTHAM, MA
NERV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NERV
Minerva Neurosciences Inc
|
2.2301 | 15.60M | 0 | -33.65M | -20.83M | -4.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.11 | 106.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.59 | 80.61B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
649.26 | 38.82B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.55 | 31.03B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.15 | 29.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Minerva Neurosciences Inc Stock (NERV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2020-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | 開始されました | BTIG Research | Buy |
| 2019-10-02 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-09-25 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-18 | 開始されました | William Blair | Outperform |
| 2019-05-31 | 開始されました | H.C. Wainwright | Buy |
| 2017-09-01 | 開始されました | Citigroup | Buy |
| 2017-03-06 | 再開されました | Jefferies | Buy |
| 2016-05-12 | 再開されました | Jefferies | Buy |
すべてを表示
Minerva Neurosciences Inc (NERV) 最新ニュース
StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Now Covered by StockNews.com - Defense World
Future Industry Growth Of Cognitive Behavioral Therapy - openPR
Neurological stocks rise and fall on clinical data; index down - BioWorld Online
Minerva Neurosciences reports voting results from annual meeting By Investing.com - Investing.com Nigeria
Minerva Neurosciences stock hits 52-week low at $2.07 - Investing.com India
Minerva Neurosciences stock hits 52-week low at $2.07 By Investing.com - Investing.com UK
Minerva Neurosciences reports voting results from annual meeting - Investing.com
Minerva Neurosciences (NASDAQ:NERV) Earns Sell Rating from Analysts at StockNews.com - Defense World
Minerva Neurosciences : ROSEN, RECOGNIZED INVESTOR COUNSEL, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class ActionNERV - Marketscreener.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.25% - MSN
Reviewing Vistagen Therapeutics (NASDAQ:VTGN) and Minerva Neurosciences (NASDAQ:NERV) - Defense World
500: Something went wrong - Investing.com
Minerva Neurosciences stock hits 52-week low at $2.25 By Investing.com - Investing.com Canada
Minerva Neurosciences’ (NERV) “Neutral” Rating Reiterated at HC Wainwright - Defense World
Minerva Neurosciences Reports Positive Earnings Amid FDA Challenges - TipRanks
Minerva Neurosciences: Q3 Earnings Snapshot - San Francisco Chronicle
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Cognitive Impairment Disorders Treatment A Game Changer for Global Finance Forecast-Eli Lilly and Company, AstraZeneca, – IndiaPolitics.com - IndiaPolitics.com
Japan Receptor Tyrosine Protein Kinase ERBB 4 Industry Size, Share, Price, Trends, Forecast (2024-2034) - IndiaPolitics.com
Minerva Neurosciences (NASDAQ:NERV) Share Price Passes Below 200-Day Moving Average – What’s Next? - Defense World
Schizophrenia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion - Barchart
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Inari Medical director sells $1.83M in common stock - TipRanks
Intuitive Machines Shares Soar on NASA Pact for Near-Space Grid - Bloomberg
Intuitive Machines Stock Soars on New NASA Contract. This Is Big. - Barron's
Intuitive Machines Stock Is Soaring Wednesday: What's Going On? - Benzinga
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
After-hours movers: Intuitive Machines, Casella Waste Systems, Galmed Pharma, Edgewise Therapeutics - Investing.com Australia
Minerva Neurosciences (NASDAQ:NERV) Receives New Coverage from Analysts at StockNews.com - Defense World
Rathbones Group PLC Increases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) - MarketBeat
INmune Bio stock dips on $13M securities offering - MSN
Minerva Neurosciences (NASDAQ:NERV) versus AC Immune (NASDAQ:ACIU) Head-To-Head Survey - Defense World
Rubertis Francesco De Net Worth (2024) - GuruFocus.com
Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com - Defense World
Research Analysts Issue Forecasts for Minerva Neurosciences, Inc.’s Q3 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Price Target Cut to $5.00 - Defense World
HC Wainwright Weighs in on Minerva Neurosciences, Inc.’s Q4 2024 Earnings (NASDAQ:NERV) - Defense World
Minerva Neurosciences: Q2 Earnings Snapshot - San Antonio Express-News
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates - GlobeNewswire
Minerva Neurosciences (NASDAQ:NERV) Coverage Initiated at StockNews.com - Defense World
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200 Day Moving Average of $4.42 - Defense World
StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV) - Defense World
Minerva Neurosciences (NASDAQ:NERV) Stock Price Passes Below 200-Day Moving Average of $4.54 - Defense World
Design, Sarepta, Wave rise amid overall neurological index decline - BioWorld Online
Roche's Ocrevus Subcutaneous Gets European Commission Nod - Markets Insider
Minerva Neurosciences - The Pharma Letter
Roche's (RHHBY) Ocrevus Subcutaneous Gets European Commission Nod - Yahoo Finance
Ultragenyx (RARE) to Seek Accelerated Nod for Rare Disease Drug - Yahoo Finance
Minerva Neurosciences Inc (NERV) 財務データ
収益
当期純利益
現金流量
EPS
0.08%
0.05%
大文字化:
|
ボリューム (24 時間):